Full Year 2021 Results

2021 Sales

$93.8B Worldwide Increased ▲ **13.6%**

Excluding acquisitions/ divestitures on an operational basis: Worldwide Increased ▲ **12.8%***

Diluted Earnings Per Share

$7.81 Increased ▲ **41.7%**

Adjusted Diluted Earnings Per Share*

$9.80 Increased ▲ **22.0%**





Joaquin Duato
Chief Executive Officer
Johnson & Johnson

"Our 2021 performance reflects continued strength across all segments of our business. Guided by Our Credo, I am honored to assume the role of CEO, leading our global teams in continuing our work to deliver life-changing solutions to consumers, patients, and health care providers. Given our strong results, financial profile, and innovative pipeline we are well positioned for success in 2022 and beyond."

$14.6 Billion

Worldwide Consumer Health Sales

Consumer Health worldwide reported sales increased 4.1% or 2.8% operationally[1]. Primary operational drivers:

Neutrogena® TYLENOL® Aveeno® Motrin® IB ZYRTEC® Imodium® BAND-AID® BRAND ADHESIVE BANDAGES Aveeno® baby

$52.1 Billion

Worldwide Pharmaceutical Sales

Pharmaceutical worldwide reported sales increased 14.3% or 13.1% operationally[1]. Primary operational drivers:

Stelara® (ustekinumab) DARZALEX® (daratumumab) injection for intravenous infusion 100 mg/5 mL, 400 mg/20 mL Tremfya® (guselkumab) Erleada® (apalutamide) 60 mg tablets Uptravi® selexipag tablets 200-1600 mcg INVEGA SUSTENNA® paliperidone palmitate Opsumit® macitentan

$27.1 Billion

Worldwide Medical Devices Sales

Medical Devices worldwide reported sales increased 17.9% or 16.2% operationally[1]. Primary operational drivers:

Electrophysiology · Contact Lens · Wound Closure · Surgical Vision · Trauma · Biosurgery · Energy · Endocutters · Hips · Knees

Note: values may have been rounded

For full financial data and non-GAAP reconciliations, please refer to Johnson & Johnson's earnings release issued on January 25, 2022, available at http://www.investor.jnj.com/sales-earnings.cfm.

*Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

[1]Non-GAAP measure; excludes the impact of translational currency.

Caution Concerning Forward-Looking Statements: This document contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements, review the "Note to Investors Concerning Forward-Looking Statements" included in the Johnson & Johnson earnings release issued on January 25, 2022, as well as the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.